Ask AI
ProCE Banner Activity

Pharmacy Updates and the Evolving First-Line Treatment Landscape for Patients With EGFR-Mutated NSCLC 

Clinical Thought

Multidisciplinary oncology care between the clinical team and specialty pharmacists can help incorporate the use of newer combination regimens into therapeutic approaches for patients with advanced EGFR-mutated NSCLC. This commentary outlines some of the key ways that specialty pharmacists can help with the authorization process and the management of adverse events. 

Released: September 29, 2025

Share

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with advanced NSCLC, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with NSCLC.